TOKYO, May 14 (Reuters) - Takeda Pharmaceutical Co forecast on Tuesday it would have an operating loss in the current financial year, as it books costs associated with the multibillion-dollar Shire deal.
Japan’s biggest drugmaker expects an operating loss of 193 billion yen ($1.76 billion) for the year to March 2020, compared with a 205 billion yen profit a year earlier.
That compares with an average estimate for the current year of 227.5 billion yen profit from 12 analysts, compiled by Refinitiv.
Takeda closed a deal to acquire Irish Shire in January. ($1 = 109.60 yen) (Reporting by Takashi Umekawa; Editing by Richard Borsuk)